Limited synthetic tractability remains a major bottleneck in fragment-to-lead optimization, often slowing down or halting otherwise promising fragment-based drug discovery (FBDD) campaigns. Ideally, fragment follow-up should enable rapid, systematic expansion, delivering novel hits and lead compounds without the need for time-consuming custom synthetic route development.
Compared to conventional fragment libraries that frequently contain structures that are difficult to elaborate or lack accessible analogs, the concept of “sociable” fragments emphasizes multiple, well-defined synthetic vectors, combined with strong commercial availability of related analogs. Fragment sociability goes beyond binding affinity or structural diversity: it focuses on a fragment’s ability to generate numerous, chemically diverse and synthetically accessible analogs, enabling rapid and iterative fragment growing through straightforward chemical modifications [1]. This approach enables efficient exploration of chemical space and a smooth transition from fragment hits to optimized lead compounds.
In response to this growing need in accelerating fragment-based screening and hit-to-lead programs, our cheminformatics team has developed its original Sociable Fragment Library, distinguished by the following key features:
- About 2,900 sociable fragments available in stock
- Optimized for fragment growing and hit-to-lead optimization
- Multiple synthetic vectors per fragment
- High commercial availability of close analogs
- Designed for FBDD, SAR optimization, and challenging medicinal chemistry targets
The compound selection can be customized based on your requirements. Cherry-picking is available.
Please, contact us at orders@lifechemicals.com for any additional information and price quotations.
Representative screening compounds from the Screening Library
Background information
Fragment-based drug discovery (FBDD) has repeatedly demonstrated its effectiveness for hit identification [4,5]. However, transforming fragment hits into lead compounds remains challenging, as fragment growing often requires complex, costly, and time-intensive synthesis. Even with advances in rational design and AI-driven generative approaches, synthetic feasibility remains a critical limiting factor.
Sociable fragments are designed to overcome this challenge. They typically feature multiple functional groups, such as boronic acids, amines, or halides, enabling diverse chemical transformations including coupling, substitution, and amide formation [2]. This multiplicity of growth vectors allows medicinal chemists to explore binding interactions in three-dimensional space, reduce synthetic dead ends, and accelerate structure–activity relationship (SAR) development.
Studies show that fragment libraries enriched with sociable features significantly increase the success rate of FBDD programs [3], as they align with core medicinal chemistry requirements: predictable chemistry, scalable synthesis, and rapid hit expansion. Our Sociable Fragment Library prioritizes fragments that meet key physicochemical guidelines and are supported by a broad ecosystem of commercially available analogs, facilitating efficient hit-to-lead and SAR optimization [6]. The Library is particularly valuable for challenging targets, such as protein–protein interactions and allosteric binding sites, where stepwise fragment growth from low-affinity binders is essential [7].
Fig.1. Adapted from article: “Fragment-based drug discovery: opportunities for organic synthesis” (https://doi.org/10.1039/D0MD00375A)
Fragment selection by the concept of scaffold sociability
The Sociable Fragment Library comprises nearly 2,900 in-stock fragments optimized for fragment-based screening and downstream medicinal chemistry. The Library was constructed using a scaffold sociability-driven selection strategy based on the Life Chemicals General Fragment Library. Strict filters were applied to identify drug-like, synthetically accessible fragments that efficiently cover available synthon and scaffold space [8].
The library spans a broad range of chemical frameworks to ensure comprehensive pharmacophore coverage, while avoiding overrepresentation of flat, aromatic structures typical of legacy fragment collections. Instead, selection favors polar, three-dimensional and shape-diverse fragments, which are better suited to complex biological targets and improve ligand efficiency and selectivity [9].
Fragments were ranked using a dedicated internal scoring workflow that incorporated Rule of 3/5 compliance, bioactivity relevance, absence of bulky substituents, evaluation of reactive centers, and overall scaffold versatility. Where appropriate, virtual fragment elaboration based on reaction-based schemes was applied to assess fragment growth potential and analog availability.
Reference:
- Hann, M. M., et al. (2001). Molecular complexity and its impact on the probability of finding leads for drug discovery. Journal of Chemical Information and Computer Sciences, 41(3), 856-864.
- Morphy, R. (2010). Selectively nonselective kinase inhibitors: striking the right balance. Journal of Medicinal Chemistry, 53(4), 1413-1437.
- Lamoree, B., & Hubbard, R. E. (2017). Current perspectives in fragment-based lead discovery (FBLD). Essays in Biochemistry, 61(5), 453-464.
- Murray, C. W., & Rees, D. C. (2009). The rise of fragment-based drug discovery. Nature Chemistry, 1(3), 187-192.
- Roughley, S. D., & Jordan, A. M. (2011). The medicinal chemist’s toolbox: an analysis of reactions used in the pursuit of drug candidates. Journal of Medicinal Chemistry, 54(10), 3451-3479.
- Erlanson, D. A., et al. (2016). Twenty years on: the impact of fragments on drug discovery. Nature Reviews Drug Discovery, 15(9), 605-619.
- Arkin, M. R., & Wells, J. A. (2004). Small-molecule inhibitors of protein–protein interactions: progressing towards the dream. Nature Reviews Drug Discovery, 3(4), 301-317.
- Congreve, M., et al. (2003). A ‘rule of three’ for fragment-based lead discovery? Drug Discovery Today, 8(19), 876-877.
- Lovering, F., et al. (2009). Escape from flatland: increasing saturation as an approach to improving clinical success. Journal of Medicinal Chemistry, 52(21), 6752-6756.
- Wójcikowski, M., Zielenkiewicz, P. & Siedlecki, P. Open Drug Discovery Toolkit (ODDT): a new open-source player in the drug discovery field. J Cheminform 7, 26 (2015). https://doi.org/10.1186/s13321-015-0078-2.